Merck KGaA

Merck KGaA

Merck KGaA

Overview
Date Founded

1995

Headquarters

Frankfurter Strasse 250, Darmstadt, 64293, DEU

Type of Company

Public

Employees (Worldwide)

57K

Industries

Pharmaceuticals
Hospitals & Patient Services
Biotechnology

Company Description

Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. It operates through the following sectors: Healthcare, Life Science, Performance Materials and Corporate & Other. The Healthcare sector discovers, develops, and produces prescription medicines used to treat cancer, multiple sclerosis, and infertility. The Life Science sector provides scientists with laboratory materials, technologies, and services. The Performance Materials sector offers specialty chemicals and materials for demanding applications. The firm offers pharma and biopharma manufacturing, pharmaceutical research, pharma quality control, and government and academic research services. The company was founded by Friedrich Jacob Merck in 1668 and is headquartered in Darmstadt, Germany.

Contact Data
Trying to get in touch with decision makers at Merck KGaA? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Chief Executive Officer

Chief Financial Officer

Chief Information Officer

Chief Strategy Officer & Executive Vice President

Chief Human Resources Officer

Chief Executive Officer, Life Science & Performance Materials

Chief Executive Officer, Performance Materials

Chief Executive Officer of Consumer Health

Global Chief of Staff & Head-Strategy Realization Office

Supervisory Board

Chief Executive Officer at Exyte AG

Professor at Johann Wolfgang Goethe-Universität Frankfurt am Main

Deputy Chairman of the Supervisory Board at Evonik Industries AG

Vice President, Corporate Quality Assurance at Merck KGaA

Global Product Manager, Inorganic Reagents at Merck KGaA

Professional at Merck KGaA

District Manager at Industriegewerkschaft Bergbau Chemie Energie

Chairman, Works Council Merck Darmstadt & Gernsheim at Merck KGaA

Chief Financial Officer at Vonovia SE

Professional at Merck KGaA

Paths to Merck KGaA
Potential Connections via
Relationship Science
You
Merck KGaA
Owners & Shareholders
Details Hidden

SEG offers a long-only equity management program that utilizes fundamental analysis to select stocks they believe will provide better than market returns over a complete market cycle. Money market reserves may comprise 0 to 50 percent of the account, but generally range from 0 to 20 percent, depending on market conditions. SEG generally limits their portfolio of securities to less than 40 than stocks in each account. SEG employs eight primary investment strategies. Their investment strategies are generally driven by a research-intensive, fundamental bottom-up process and draw upon a centralized research department. These strategies include: Small-Mid Cap /Long-Only, US Core, Concentrated Opportunistic, US Long/Short, International Long/Short, International Long-Only, Global Long-Only, and Private Equity. SEG obtains exposure to particular issuers or securities for their private funds (and may for individual clients) through various types of derivatives transactions, including swaps and contracts for differences. In addition, they may hedge exposure to currency fluctuations for foreign securities owned by the private funds by entering into currency forward or option transactions.

Details Hidden

Amundi-IM invests through funds in all asset classes and main currencies. The firm believes that overall analysis of a company, including economic, social and environmental aspects, allows for better assessment of the risks and opportunities that may affect its long-term valuation.

Details Hidden

JOHCM is a long-term, growth-oriented, bottom-up manager which operate as a stand-alone boutique, investing six equity asset classes: the UK, Europe, US, Asia, Global and Global Emerging Markets, and their recently launched multi asset product, which are all offered to clients in a variety of countries worldwide through segregated mandates and in some countries, funds. These equity strategies cover UK, Pan and Continental Europe, US, Japan, Global, International, Asian and Emerging Markets strategies. JOHCM manages long-only OEIC funds, private equity and activist funds. In addition, a number of their other funds employ an active value approach, where shareholders are involved in the governance and daily operations of the businesses in which they invest.

Recent Transactions
Details Hidden

EMD Millipore Corporation, Merck KGaA purchase RESOLUTION Spectra Systems SAS

Details Hidden

FlexEnable Ltd., Plastic Logic JSC purchase Merck KGaA /Otft Materials Portfolio from Merck KGaA

Details Hidden

EMD Millipore Corporation, Merck KGaA purchase FloDesign Sonics, Inc. from Bright Capital LLC, Dynamk Capital

Transaction Advisors
Accountant

Advised onClayton Dubilier & Rice LLC purchases VWR International LLC from Merck KGaA

Legal Advisor

Advised onMerck KGaA purchases Sigma-Aldrich Corp.

Investment Advisor

Advised onMerck KGaA purchases Sigma-Aldrich Corp.

Legal Advisor

Advised onMerck KGaA purchases Sigma-Aldrich Corp.

Legal Advisor

Advised onMerck KGaA purchases Sigma-Aldrich Corp.

Legal Advisor

Advised onLuminex Corp. purchases EMD Millipore Corp. /Flow Cytometry Assets from Merck KGaA

Advisors & Consultants
Advisor

President & Chief Executive Officer at American Association of Advertising Agencies

Legal Advisor

Senior Advisor at Keystone National Properties

Legal Advisor

Managing Partner at Baker & McKenzie LLP

Clients

Texas Instruments Incorporated engages in the design, manufacture, test, and sell analog and embedded semiconductors, which include industrial, automotive, personal electronics, communications equipment, and enterprise systems. It operates through the following segments: Analog and Embedded Processing. The Analog segment semiconductors change real-world signals, such as sound, temperature, pressure or images, by conditioning them, amplifying them and often converting them to a stream of digital data that can be processed by other semiconductors, such as embedded processors. The Embedded Processing segment designed to handle specific tasks and can be optimized for various combinations of performance, power and cost, depending on the application. The company was founded by Cecil H. Green, Patrick Eugene Haggerty, John Erik Jonsson, and Eugene McDermott in 1930 and is headquartered in Dallas, TX.

Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1998 and is headquartered in Bothell, Washington.

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Key Stats and Financials As of 2019
Market Capitalization
$69.7B
Total Enterprise Value
$66.6B
Earnings Per Share
$3.47
EBITDAMargin
24.18%
Enterprise Value / Sales
3.61x
Enterprise Value EBITDAOperating
14.91x
TEVNet Income
44.12x
Debt TEV
0.23x
Three Year Compounded Annual Growth Rate Of Revenue
2.44%
Revenue
$18.5B
Net Profit
$1.51B
EBITDA
$4.46B
Total Debt
$15.1B
Total Equity
$20.5B
Non-Profit Donations & Grants
Non-Profit Donations & Grants Received
Investments
Details Hidden

BioVascular, Inc. develops drugs and devices for control of intimal hyperplasia associated with vascular procedures. It is a integrated specialty cardiovascular therapeutic company, and to utilize corporate partnerships in markets that have complex marketing barriers and/or combination technologies. The company was founded by John H. Parrish and Paul F. Glidden in 2005 and is headquartered in San Diego, CA.

Details Hidden

Verva Pharmaceuticals Ltd. developed therapies to treat diabetes. Its products include insulin sensitizers, insulin secretagogues, fat formation inhibitors for the prevention, treament of obesity, drug-induced weight gain and insulin secretion modulators. The company was founded in 1996 and was headquartered in Geelong, Australia.

Details Hidden

Archemix Corp. engages in the research and development of aptamer-based therapeutic products. It focuses in the areas of cardiovascular disease hematology, and oncology. The company was founded in May 2001 and is headquartered in Cambridge, MA.

Investors
Details Hidden

Co-Founder at Avista Capital Partners

Suppliers
Bristol-Myers Squibb Company Medical Support Services | New York, New York

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

Eli Lilly & Company Hospitals & Patient Services

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm’s products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity. The Oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. The Immunology products include Olumiant and Taltz. The Neuroscience products consist of Cymbalta, Emgality, Reyvow, and Zyprexa. The Other therapies include Bamlanivimab, Cialis, and Forteo.The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Juniper Pharmaceuticals, Inc. Biotechnology | Boston, MA

Columbia Laboratories has a rich heritage in pharmaceutical research and development that has helped place the company on the forefront of women's healthcare and drug delivery. Our products use the principles of bioadhesion to achieve controlled, sustained delivery of hormones and other compounds that are difficult to administer.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Merck KGaA. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Merck KGaA's profile does not indicate a business or promotional relationship of any kind between RelSci and Merck KGaA.